BCL9/9L proteins enhance the transcriptional output of the β-catenin/TCF transcriptional
complex and contribute critically to upholding the high WNT signaling level required for …

Consensus abstract Background The management of primary rectal cancer beyond total
mesorectal excision planes (PRC‐bTME) and recurrent rectal cancer (RRC) is challenging …

Background: One of the main chemotherapeutic drugs used on a routine basis in patients
with metastatic colorectal cancer ((m) CRC) is the topoisomerase-1 inhibitor, irinotecan …

(Mawdsley et al., 2005) and poorer overall survival (OS)(Wibe et al., 2002), even after TME
(Marijnen et al., 2003). The CRM can be involved by direct or discontinuous tumour spread …

Background: High-level microsatellite instability (MSI-H) has been reported as a prognostic
marker in colon cancer. We here analysed the prognostic significance of MSI and mutations …

A draft addendum to ICH E9 has been released for public consultation in August 2017. The
addendum focuses on two topics particularly relevant for randomized confirmatory clinical …

Colorectal cancer (CRC) is one of the commonest cancers with 1.2 million new cases
diagnosed each year in the world. It remains the fourth most common cause of cancer …

Molecularly targeted agents have improved the outcome of patients with metastatic
colorectal cancer (CRC) and other advanced malignant diseases. In fact, several phase III …

Composite outcome measures such as progression-free survival and disease-free survival
are increasingly used as surrogate end points in oncology research, frequently serving as …

Background With the large amount of biological data that is currently publicly available,
many investigators combine multiple data sets to increase the sample size and potentially …